247 related articles for article (PubMed ID: 10346712)
1. A whole new world?: pharmaceutical responses to the managed care revolution.
Balto DA
Food Drug Law J; 1997; 52(1):83-98. PubMed ID: 10346712
[No Abstract] [Full Text] [Related]
2. The response to health care reform by the pharmaceutical industry.
Krulwich AS
Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
[No Abstract] [Full Text] [Related]
3. The need for health care reform.
Mossinghoff GJ
Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
[No Abstract] [Full Text] [Related]
4. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
Seay M
Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
[No Abstract] [Full Text] [Related]
5. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs.
Food Drug Law J; 1998; 53(1):25-34. PubMed ID: 11795334
[No Abstract] [Full Text] [Related]
6. Too big? Caremark, AdvancePCS getting close look from feds.
Becker C
Mod Healthc; 2004 Jan; 34(2):14, 16. PubMed ID: 14959629
[No Abstract] [Full Text] [Related]
7. The potential for self-interested behavior by pharmaceutical manufacturers through vertical integration with pharmacy benefit managers: the need for a new regulatory approach.
Mitchell EL
Food Drug Law J; 1999; 54(1):151-83. PubMed ID: 11758556
[No Abstract] [Full Text] [Related]
8. Eliminating innovation: how price controls limit access.
Ingram J
J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
[No Abstract] [Full Text] [Related]
9. Health care reform and the pharmaceutical industry.
Mossinghoff GJ
Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of pharmacy benefits management firms in a managed care environment.
O'Leary JS
Benefits Q; 1995; 11(3):24-33. PubMed ID: 10151118
[TBL] [Abstract][Full Text] [Related]
11. Provider boycotts--a review of the Merck-Medco decision. Merck-Medco Managed Care L.L.C. v. Rite Aid Corporation.
Becker S
Health Care Law Mon; 2000 May; ():10-8. PubMed ID: 14743588
[No Abstract] [Full Text] [Related]
12. The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach.
Kuhlik BN
Food Drug Law J; 1995; 50(1):23-48. PubMed ID: 10342984
[No Abstract] [Full Text] [Related]
13. PBMs raise the curtain.
Sipkoff M
Manag Care; 2006 Sep; 15(9):38-40, 43. PubMed ID: 17036937
[No Abstract] [Full Text] [Related]
14. The effects of managed care on the retail distribution of pharmaceuticals.
Carroll NV
Manag Care Interface; 1998 Nov; 11(11):105-8, 111-3. PubMed ID: 10187415
[TBL] [Abstract][Full Text] [Related]
15. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
Whitener MD
Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
[No Abstract] [Full Text] [Related]
16. A conversation with Debra Dullinger, PharmD.
Dullinger D
Med Interface; 1994 Oct; 7(10):71-4. PubMed ID: 10137568
[TBL] [Abstract][Full Text] [Related]
17. How MCOs can get optimal value from their pharmacy benefit managers.
Jones JD
Manag Care; 2008 May; 17(5):43-5. PubMed ID: 18567468
[No Abstract] [Full Text] [Related]
18. Pharmaceutical industry and payer partnerships to manage costs and improve quality.
Mauch RP
Manag Care; 2001 Sep; 10(9 Suppl):2-4; discussion 9-12. PubMed ID: 11729438
[No Abstract] [Full Text] [Related]
19. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
MacEachern L
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
[TBL] [Abstract][Full Text] [Related]
20. Is it risky to ride with a drug company?
McCarthy R
Bus Health; 1996 Jan; 14(1):30-4, 36. PubMed ID: 10156381
[No Abstract] [Full Text] [Related]
[Next] [New Search]
